EHA 2024 - AI for Enhanced Bone Marrow Analysis
We're delighted to announce two of our abstracts have been accepted for presentation at the European Hematology Association 2024 Conference.
Ground Truth Labs
Team
News and insights
GTL Shortlisted for Cancer Research Horizons New Startup of the Year Award
GTL's AI biomarker platform recognized for its potential to revolutionize cancer diagnosis and treatment.
Ground Truth Labs
Team
Insights from ASH 2023: Advancements in MPN Research
Ground Truth Labs highlights ASH 2023's innovative MPN therapies and advances AI-driven fibrosis assessment to revolutionize treatment approaches.
Róisín NicAmhlaoibh
VP Business Development
MPN Hub discusses AI in the future of bone marrow histopathology
Daniel Royston, pathology lead at Ground Truth Labs, discusses the role of AI in bone marrow histology with MPN Hub.
Daniel Royston
Pathology Lead
Recognising blood cancer awareness month 2023
The vital role of novel research and development in tackling blood cancers like myeloproliferative neoplasms and myeloma.
Ground Truth Labs
Team
AI biomakers to transform oncology
AI biomarkers will transform oncology with new maps for tumor biology and breakthrough predictors for treatment response. We have the opportunity to improve outcomes for every cancer patient with AI-driven insights from digital pathology.
Alan Aberdeen
Co-founder
GTL raises $4.3M to launch commercially with AI biomarkers
Today, Ground Truth Labs (GTL), is thrilled to announce its launch into the wider healthtech space. Backed by a $4.3M funding round led by Oxford Science Enterprises
Ground Truth Labs
Team